Biweekly Administration of Cisplatin/Gemcitabine in Advanced Nonsmall Cell Lung Cancer

López-Vivanco, G.; Viteri, A.; Barceló, Ramón; Muñoz, Alberto; Rubio, I.; Mañé, J. M.; Fuente, Natalia de la

doi:10.1097/01.coc.0000170583.42741.cd

Cited by 12 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be stressed that this was an unplanned analysis, subjective to biases and, therefore, this finding can only be considered as 'hypothesis generating'. Finally, the mild toxicity profile of DD-GC, similarly to the results of the only other study using biweekly gemcitabine at 2500 mg/m 2 combined with 50 mg/m 2 of cisplatin in NSCLC patients [14], indicates that higher gemcitabine doses could be safely used. Biweekly gemcitabine at doses of up to 3000 mg/m 2 has been used in combination with other agents, such as capecitabine, paclitaxel and vinorelbine [15,21,26].…”

Section: Treatment Details and Toxicity Analysissupporting

confidence: 57%

“…The G-CSF was administered on days 5-9. The dose of gemcitabine was based on the only data available at the time of the design of the study regarding the combination of high-dose gemcitabine with cisplatin [14]. This regimen resulted in a twofold increase in the DI of cisplatin and 1.66-fold increase of gemcitabine, compared with the standard GC [6].…”

Section: Selection and Randomizationmentioning

confidence: 99%

“…Furthermore, Sternberg et al have shown that biweekly paclitaxel (Taxol) and gemcitabine at 2.5-3 g/m 2 achieved a 60% RR in patients with advanced UC who had previously received MVAC, albeit some as perioperative treatment [13]. Apart from paclitaxel, high-dose gemcitabine can be combined with other agents, including cisplatin: in a recent, phase II study, in NSCLC, gemcitabine at 2.5 g/m 2 was safely combined with cisplatin at 50 mg/m 2 [14], while in a randomized, phase II study in pancreatic cancer, gemcitabine at 2.2 g/m 2 was safely combined with capecitabine [15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

et al. 2013

View full text Add to dashboard Cite

Background: The combinations of methotrexate, vinblastine, Adriamycin, cisplatin (Pharmanell, Athens, Greece) (MVAC) or gemcitabine, cisplatin (GC) represent the standard treatment of advanced urothelial cancer (UC). Dosedense (DD)-MVAC has achieved longer progression-free survival (PFS) than the conventional MVAC. However, the role of GC intensification has not been studied. We conducted a randomized, phase III study comparing a DD-GC regimen with DD-MVAC in advanced UC. Results: The median overall survival (OS) and PFS were 19 and 8.5 months for DD-MVAC and 18 and 7.8 months for DD-GC (P = 0.98 and 0.36, respectively). Neutropenic infections were less frequent for DD-GC than for DD-MVAC (0% versus 8%). More patients on DD-GC received at least six cycles of treatment (85% versus 63%, P = 0.011) and the discontinuation rate was lower for DD-GC (3% versus 13%). Patients and methods:Conclusions: Although DD-GC was not superior to DD-MVAC, it was better tolerated. DD-GC could be considered as a reasonable therapeutic option for further study in this patient population.Clinical Trial Number: ACTRN12610000845033, www.anzctr.org.au.

show abstract

Section: Treatment Details and Toxicity Analysissupporting

confidence: 57%

Section: Selection and Randomizationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…LopezVivanco et al [16] reported their experience with the biweekly administration of cisplatin and gemcitabine in the treatment of advanced NSCLC. The overall response rate was 38.8% and the median overall survival was 48 weeks.…”

Section: Discussionmentioning

confidence: 99%

Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Hematologic toxicity was less severe with a modified regimen employing a 3-week cycle with gemcitabine administration on d 1 and 8 [9][10][11][12][13] . In addition, both gemcitabine and cisplatin were given to patients with stage IIIB or IV NSCLC on the first day of every 2-week period [14] . However, the optimal schedule of combination chemotherapy with gemcitabine and cisplatin remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

Fan

Lin

et al. 2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

npg Aim: To investigate the pharmacodynamics and pharmacokinetics of gemcitabine (dFdC) administered on d 1 and 5 plus cisplatin administered on d 1 in chemonaive patients with stage IIIB or IV non-small cell lung cancer (NSCLC). Methods: In each combination cycle, gemcitabine was administered at a dose of 1250 mg/m 2 as a 30 min intravenous (iv) infusion on d 1 and 5 followed by cisplatin at a dose of 75 mg/m 2 as a 3 h iv infusion on d 1 every 3 weeks. There was an interval of 1 h between the two infusions. Clinical response and toxicity of the regimen were observed. Furthermore, the plasma concentrations of gemcitabine (dFdC) and its metabolite (dFdU) at different time points were detected during the first cycle of infusion. Pharmacokinetic software (PKS) was used to estimate the pharmacokinetic parameters of gemcitabine and its metabolite dFdU. Results: A total of 28 patients was enrolled in the study. The median age was 54 years (range 27-75 years), and most patients were in good clinical condition. Twenty-seven patients received two or more treatment cycles. The overall clinical response rate was 33.3%. The median overall survival time was 13 months. The estimated median time to tumor progression (TTP) was 6.2 months, and the 1-year survival rate was 55.6%. Toxicities were tolerated. The main toxicity was myelosuppression; 35.7% of patients had grade 3/4 hemato-logic toxicities and 28.6% had grade 3/4 non-hematologic toxicities, which were commonly gastrointestinal responses. The pharma-cokinetic parameters of dFdC and dFdU were not different between pre-and post-administration of gemcitabine on d 1 and 5. dFdU was minimal (0.729±0.637 μg/mL) before gemcitabine was infused on d 5, and gemcitabine was not present. Conclusion: The regimen is active and well tolerated in chemonaive patients with advanced NSCLC. After gemcitabine was administered on d 1 and 5, the pharmacokinetic parameters of dFdC and dFdU showed no difference from those before the infusion, and dFdU was minimal before gemcitabine was administered on d 5.

show abstract

Biweekly Administration of Cisplatin/Gemcitabine in Advanced Nonsmall Cell Lung Cancer

Abstract: The schedule of cisplatin and gemcitabine analyzed is active with a good therapeutic index.

Cited by 12 publications

References 25 publications

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial

Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

Contact Info

Product

Resources

About